Gut Microbiota Composition Before and After Use of Proton Pump Inhibitors
Open accessThe DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recently, problems associated with proton pump inhibitor (PPI) use have begun to surface. PPIs influence the gut microbiota; therefore, PPI use may increase the risk of enteric infections and cause bacterial translocation. In this study, we investigated fecal microbiota composition, fecal organic acid concentrations and pH, and gut bacteria in the blood of the same patients before and after PPI use. METHODS: Twenty patients with reflux esophagitis based on endoscopic examination received 8 weeks of treatment with PPIs. To analyze fecal microbiota composition and gut bacteria in blood and organic acid concentrations, 16S and 23S rRNA-targeted quantitative RT-PCR and high-performance liquid chromatography were conducted. RESULTS: Lactobacillus species were significantly increased at both 4 and 8 weeks after PPI treatment compared with bacterial counts before treatment (P = 0.011 and P = 0.002, respectively). Among Lactobacillus spp., counts of the L. gasseri subgroup, L. fermentum, the L. reuteri subgroup, and the L. ruminis subgroup were significantly increased at 4 and 8 weeks after treatment compared with counts before treatment. Streptococcus species were also significantly increased at 4 and 8 weeks after PPI treatment compared with counts before treatment (P < 0.01 and P < 0.001, respectively). There was no significant difference in the total organic acid concentrations before and after PPI treatment. Detection rates of bacteria in blood before and after PPI treatment were 22 and 28%, respectively, with no significant differences. CONCLUSIONS: Our quantitative RT-PCR results showed that gut dysbiosis was caused by PPI use, corroborating previous results obtained by metagenomic analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, antibiotics (except vancomycin),4”
From Custom scoring based on ecological topology of gut microbiota associated with cancer immunotherapy outcome (2024) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823 · cited 1×
“Recently, bacterial rRNA gene-based, metagenomic analyses have been conducted to analyze the composition of the human gut microbiome [22, 23, 42, 43].”
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762 · cited 1×
“Recently, bacterial rRNA gene-based, metagenomic analyses have been conducted to analyze the composition of the human gut microbiome [22, 23, 42, 43].”
Lundell, L. R., Dent, J., Bennett, J. R., Blum, A. L., Armstrong, D., Galmiche, J. P., Johnson, F., Hongo, M., Richter, J. E., Spechler, S. J., et al. (1999) · Gut · doi:10.1136/gut.45.2.172 · Cited by 2,305 · cited 1×
“All patients were at least 20 years of age and had been shown to have ≥ grade A reflux esophagitis according to the Los Angeles classification [31] by endoscopic examination within 6 months prior to recruitment.”
Control of pathogens and pathobionts by the gut microbiota
Kamada, N., Chen, G. Y., Inohara, N., & Núñez, G. (2013) · Nature Immunology · doi:10.1038/ni.2608 · Cited by 1,625 · cited 1×
“The gut microbiota plays an important role in host resistance against colonization by exogenous enteric microbes and overgrowth of indigenous commensals [18].”
Proton pump inhibitors affect the gut microbiome
Imhann, F., Bonder, M. J., Vich Vila, A., Fu, J., Mujagic, Z., Vork, L., Tigchelaar, E. F., Jankipersadsing, S. A., Cenit, M. C., Harmsen, H. J. M., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310376 · Cited by 1,371 · cited 14×
“Previous large cohort studies of PPI users and intervention studies of PPI use for 4 weeks reported increases in bacteria from the genus Streptococcus [19, 20, 22, 23].”
InfluentialMicroorganisms with Claimed Probiotic Properties: An Overview of Recent Literature
Fijan, S. (2014) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph110504745 · Cited by 1,059 · cited 1×
“The biological effects of probiotics are strain specific [58], and whether these bacteria have probiotic features is determined by a coevolutionary relationship between the bacteria and their hosts [59].”
Proton pump inhibitors alter the composition of the gut microbiota
Jackson, M. A., Goodrich, J. K., Maxan, M.-E., Freedberg, D. E., Abrams, J. A., Poole, A. C., Sutter, J. L., Welter, D., Ley, R. E., Bell, J. T., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-310861 · Cited by 895 · cited 14×
“Previous large cohort studies of PPI users and intervention studies of PPI use for 4 weeks reported increases in bacteria from the genus Streptococcus [19, 20, 22, 23].”
InfluentialMatsuki, T., Watanabe, K., Fujimoto, J., Miyamoto, Y., Takada, T., Matsumoto, K., Oyaizu, H., & Tanaka, R. (2002) · Applied and Environmental Microbiology · doi:10.1128/aem.68.11.5445-5451.2002 · Cited by 657
Self-citationMatsuki, T., Watanabe, K., Fujimoto, J., Takada, T., & Tanaka, R. (2004) · Applied and Environmental Microbiology · doi:10.1128/aem.70.12.7220-7228.2004 · Cited by 655
Systematic review of the risk of enteric infection in patients taking acid suppression
Leonard, J., Marshall, J. K., & Moayyedi, P. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01275.x · Cited by 633
Cited by
Dysbiosis of the gut and lung microbiome has a role in asthma
Hufnagl, K., Pali-Schöll, I., Roth-Walter, F., & Jensen-Jarolim, E. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-019-00775-y · Cited by 364
Derosa, L., Iebba, V., Silva, C. A. C., Piccinno, G., Wu, G., Lordello, L., Routy, B., Zhao, N., Thelemaque, C., Birebent, R., et al. (2024) · Cell · doi:10.1016/j.cell.2024.05.029 · Cited by 198
The role of oral bacteria in inflammatory bowel disease
Read, E., Curtis, M. A., & Neves, J. F. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00488-4 · Cited by 193
The microbiome and cancer for clinicians
Picardo, S. L., Coburn, B. A., & Hansen, A. R. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.06.004 · Cited by 151
Mechanisms of proton pump inhibitor‐induced hypomagnesemia
Gommers, L. M. M., Hoenderop, J. G. J., & de Baaij, J. H. F. (2022) · Acta Physiologica · doi:10.1111/apha.13846 · Cited by 167
Kiecka, A., & Szczepanik, M. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00489-x · Cited by 138
“showed no differences in pH values and organic acid concentrations before and after PPIs [40].”
BackgroundAssociation Between Proton Pump Inhibitor Use and Risk of Asthma in Children
Wang, Y., Wintzell, V., Ludvigsson, J. F., Svanström, H., & Pasternak, B. (2021) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.5710 · Cited by 78
Salivary microbiome with gastroesophageal reflux disease and treatment
Kawar, N. I., Park, S. G., SCHWARTZ, J. L., Callahan, N. F., Obrez, A., Yang, B. J., Chen, Z., & Adami, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-020-80170-y · Cited by 78
Rossi, G., Pezzuto, A., Sini, C., Tuzi, A., Citarella, F., McCusker, M. G., Nigro, O., Tanda, E., & Russo, A. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.07.005 · Cited by 66
Gajdács, M., & Spengler, G. (2019) · Antibiotics · doi:10.3390/antibiotics8040270 · Cited by 62
Meta-analysis of the effects of proton pump inhibitors on the human gut microbiota
Zhang, J., Zhang, C., Zhang, Q., Yu, L., Chen, W., Xue, Y., & Zhai, Q. (2023) · BMC Microbiology · doi:10.1186/s12866-023-02895-w · Cited by 74
“Although Imhann and Hojo described an increase in Enterobacteriaceae in the gut microbiota of PPI users in three cohorts, we were unable to replicate this phenomenon in the meta-analysis [2, 55].”
BackgroundYoshihara, T., Oikawa, Y., Kato, T., Kessoku, T., Kobayashi, T., Kato, S., Misawa, N., Ashikari, K., Fuyuki, A., Ohkubo, H., et al. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1758290 · Cited by 61
“Lactobacillus is reported to increase after PPI administration, although the mechanism by which this occurs is unclear.(27,29) It may be caused by the interactions of other gut microbiota that are affected by PPI administration.”
BackgroundKamath, S., Stringer, A. M., Prestidge, C. A., & Joyce, P. M. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2233900 · Cited by 60
“This diminishes the natural gastric barrier and subsequently allows for oral bacteria, otherwise incapable of surviving the gastric environment, to migrate to the gastro-intestinal tract where they may behave as opportunistic pathogens by competing with commensal bacteria [48”
BackgroundCystic Fibrosis-Related Gut Dysbiosis: A Systematic Review
Caley, L. R., White, H., de Goffau, M. C., Floto, R. A., Parkhill, J., Marsland, B. J., & Peckham, D. G. (2023) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07812-1 · Cited by 61
Effect of Proton Pump Inhibitors on Colorectal Cancer
Sasaki, T., Mori, S., Kishi, S., Fujiwara‐Tani, R., Ohmori, H., Nishiguchi, Y., Hojo, Y., Kawahara, I., Nakashima, C., Fujii, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113877 · Cited by 49
“It has been reported that reduction of intestinal acidity by PPI results in alteration of intestinal bacterial flora [31].”
BackgroundEffects of Proton Pump Inhibitors on the Small Bowel and Stool Microbiomes
Weitsman, S. R., Celly, S., Leite, G., Mathur, R., Sedighi, R., Barlow, G. M., Morales, W., Sanchez, M., Parodi, G., Villanueva-Millán, M. J., et al. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-06857-y · Cited by 50
Yin, Y., Sripetchwandee, J., Chattipakorn, N., & Chattipakorn, S. C. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102361 · Cited by 46
Shah, A., Talley, N. J., Koloski, N. A., Macdonald, G. A., Kendall, B. J., Shanahan, E. R., Walker, M. M., Keely, S., Jones, M. P., Morrison, M., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15786 · Cited by 42
Peng, K., Chen, K., Teply, B. A., Yee, G. C., Farazi, P. A., & Lyden, E. R. (2022) · Annals of Pharmacotherapy · doi:10.1177/10600280211033938 · Cited by 40
Helicobacter pylori and oral–gut microbiome: clinical implications
El-Ghannam, M., Hassanien, M. H., Ameen, Y. A., Turky, E. A., ELattar, G. M., Ray, A. A. E., & Eltalkawy, M. D. (2023) · Infection · doi:10.1007/s15010-023-02115-7 · Cited by 47
“Several factors can affect the gastric microbiome such as diet, aging, geographic area of residence, and medications like PPI and antibiotics [70, 71].”
BackgroundGastrointestinal Microbiome – What We Need to Know in Clinical Practice
Ortigão, R., Pimentel‐Nunes, P., Dinis-Ribeiro, M. J., & Libânio, D. (2020) · GE Portuguese Journal of Gastroenterology · doi:10.1159/000505036 · Cited by 46
Gulnaz, A., Nadeem, J., Han, J., Lew, L.-C., Son, J.-D., Park, Y.-H., Rather, I. A., & Hor, Y.-Y. (2021) · Biology · doi:10.3390/biology10040348 · Cited by 44
Gately, S. T. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_10 · Cited by 43
Influence of immunomodulatory drugs on the gut microbiota
Cohen, I., Ruff, W. E., & Longbrake, E. E. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.009 · Cited by 39
Shimizu, H., Arai, K., Asahara, T., Takahashi, T., Tsuji, H., Matsumoto, S., Takeuchi, I., Kyodo, R., & Yamashiro, Y. (2021) · BMC Microbiology · doi:10.1186/s12866-021-02325-9 · Cited by 37
Self-citationProton Pump Inhibitors and Oral–Gut Microbiota: From Mechanism to Clinical Significance
Zhang, X., Li, Q., Xia, S., He, Y., Liu, Y., Yang, J., & Xiao, X. (2024) · Biomedicines · doi:10.3390/biomedicines12102271 · Cited by 46
“Several small-scale observational studies have also demonstrated an association between PPI usage and composition alterations in the gut microbiota [21,25–27].”
BackgroundSun, Q., Wang, H., Sun, S.-D., Zhang, X., & Zhang, H. (2019) · World Journal of Gastroenterology · doi:10.3748/wjg.v25.i17.2110 · Cited by 40
RetractedVinke, P., Wesselink, E., van Orten-Luiten, A. C. B., & van Norren, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21010323 · Cited by 35
“As a consequence, the pH of the proximal intestine is increased [29,32], which can affect the gut microbiome [33,34].”
BackgroundSingh, G., Haileselassie, Y., Briscoe, L., Bai, L., Patel, A., Sanjines, E., Hendler, S., Singh, P. K., Garud, N. R., Limketkai, B. N., et al. (2022) · Clinical Nutrition ESPEN · doi:10.1016/j.clnesp.2021.11.005 · Cited by 30
Impact of non-antibiotic drugs on the human intestinal microbiome
Bastard, Q. L., Berthelot, L., Soulillou, J., & Montassier, E. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1952075 · Cited by 35
“Several lactobacillus species were also increased after four and eight weeks PPI use; so did facultatively anaerobic Enterobacteriaceae and Staphylococcus at eight weeks [33].”
BackgroundPotential effects of the most prescribed drugs on the microbiota-gut-brain-axis: A review
Garg, K., & Mohajeri, M. H. (2024) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2024.110883 · Cited by 34
“Many of the aforementioned bacterial groups are found in the oral cavity, throat and nasal cavity, suggesting the translocation of bacteria to lower gut areas due to reduced stomach acidity resulting from the use of PPIs (Hojo et al., 2018).”
Gastric precancerous lesions:occurrence, development factors, and treatment
Cao, Y., Wang, D., Mo, G., Peng, Y., & Li, Z. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1226652 · Cited by 32
“HP can control gastric acidity, which promotes bacterial growth and disrupts the flora in the stomach (25, 26).”
BackgroundJohnson, J. E., Dellon, E. S., McCoy, A. N., Sun, S., Jensen, E. T., Fodor, A. A., & Keku, T. O. (2021) · Journal of Gastrointestinal and Liver Diseases · doi:10.15403/jgld-3049 · Cited by 23
“PPIs are known to have an effect on the microbiome [55-57], but a large proportion (two-thirds) of the controls were also on PPIs at the time of sample collection, thus making a PPI effect less likely.”
BackgroundOmori, K., Miyakawa, H., Watanabe, A., Nakayama, Y., Lyu, Y., Ichikawa, N., Sasaki, H., & Shibata, S. (2021) · Nutrients · doi:10.3390/nu13010152 · Cited by 24
“However, the Lactobacillus abundance ratio in feces increased with PPI administration in the previous studies [51,54].”
ResultPrognostic impact of proton pump inhibitors for immunotherapy in advanced urothelial carcinoma
Okuyama, Y., Hatakeyama, S., Numakura, K., Narita, T., Tanaka, T. D., Miura, Y., Sasaki, D., Noro, D., Tokui, N., Okamoto, T., et al. (2021) · BJUI Compass · doi:10.1002/bco2.118 · Cited by 26
“In addition, PPI use can induce a significantly lower abundance of gut commensals and microbial diversity within 4 weeks, with a significant change in the abundance of Lactobacillus and Streptococcus species.(12,27) However, the immunological functions of these bacteria remain unclear and the presence or absence of sp…”
BackgroundProton Pump Inhibitors Increase the Risk of Autoimmune Diseases: A Nationwide Cohort Study
Lin, S.-H., Chang, Y., Lin, T., Hu, L.-F., Hou, T., Hsu, H., Shen, Y.-C., Kuo, P., Chen, W., Lin, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.736036 · Cited by 24
“The dysbiosis was found most often at 4 to 8 weeks after PPIs treatment in patients (14).”
BackgroundEnteral feeding and the microbiome in critically ill children: a narrative review
Fan, L., & Lee, J. H. (2021) · Translational Pediatrics · doi:10.21037/tp-20-349 · Cited by 22
“Staphylococcus, genus (20-22) • Increase enteric infections by Clostridium difficile,”
Importance of “muscle” and “intestine” training before major HPB surgery: A review
Yokoyama, Y., Nagino, M., & Ebata, T. (2020) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.835 · Cited by 19
Chronic Critical Illness: Current Aspects of the Problem (Review)
Parfenov, A., Razzhivin, V. P., & Petrova, M. V. (2022) · Современные технологии в медицине · doi:10.17691/stm2022.14.3.08 · Cited by 24
“Most pathogens do not act isolated therefore infections have “polymicrobial” phenotypes, and susceptibility to infections may be connected with the initial state of microbiota [92] and the severity of the infectious process [93].”
BackgroundTursi, A., Violi, A., Cambiè, G., Franceschi, M., Baldassarre, G., Rodriguez, K. I., Miraglia, C., Brandimarte, G., Elisei, W., Picchio, M., et al. (2020) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001787 · Cited by 18
Helicobacter pylori Related Diseases and Osteoporotic Fractures (Narrative Review)
Fisher, L., Fisher, A., & Smith, P. N. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103253 · Cited by 21
A new evaluation system for drug–microbiota interactions
Liu, T., Zhang, C., Zhang, H., Jin, J., Li, X., Liang, S., Xue, Y., Yuan, F., Zhou, Y., Bian, X., et al. (2024) · iMeta · doi:10.1002/imt2.199 · Cited by 19
“On the one hand, they can trigger inflammation and promote the ectopic colonization of microbiota in unintended locations [18, 19].”
BackgroundGut Microbiota Characteristics in Children After the Use of Proton Pump Inhibitors
Simakachorn, L., Tanpowpong, P., Chanprasertyothin, S., Thongpradit, S., & Treepongkaruna, S. (2020) · The Turkish Journal of Gastroenterology · doi:10.5152/tjg.2020.20245 · Cited by 18
Li, X., Chu, X., Cao, N., Wang, H., Fang, X.-Y., Fan, Y., Li, B., & Dong-qing, Y. (2022) · BMC Microbiology · doi:10.1186/s12866-022-02533-x · Cited by 17
Cairat, M., Rahmoun, M. A., Gunter, M. J., Severi, G., Dossus, L., & Fournier, A. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01343-1 · Cited by 18
Drugs Versus Microbiota: How Pharmacotherapy Affects Gut and Probiotic Bacteria
Zawistowska-Rojek, A., & Tyski, S. S. (2025) · Pharmaceuticals · doi:10.3390/ph18091372 · Cited by 17
“Jejunal samples from SIBO patients showed overgrowth of microaerophilic microorganisms such as Streptococcus , Staphylococcus , Escherichia and Klebsiella and anaerobes such as Bacteroides , Lactobacillus , Veillonella and Clostridium [89,90].”
Hormonal drugs: Influence on growth, biofilm formation, and adherence of selected gut microbiota
Hammouda, Z. K., Wasfi, R., & Abdeltawab, N. F. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1147585 · Cited by 19
“The effect of the tested drug compounds in this study on SCFAs production was variable and mostly independent of their effect on bacterial growth, in contrast to earlier studies’ results that a change in abundance of gut bacteria owing to drug usage was correlated to a similar effect on SCFAs production (Hojo et al.,…”
ResultA review and roadmap of the skin, lung and gut microbiota in systemic sclerosis
Teaw, S., Hinchcliff, M., & Cheng, M. (2021) · Rheumatology · doi:10.1093/rheumatology/keab262 · Cited by 15
The role of non-Helicobacter pylori bacteria in the pathogenesis of gastroduodenal diseases
Waskito, L. A., Rezkitha, Y. A. A., Vilaichone, R., Sugihartono, T., Mustika, S., Wibawa, I. D. N., Yamaoka, Y., & Miftahussurur, M. (2022) · Gut Pathogens · doi:10.1186/s13099-022-00494-0 · Cited by 19
Evidence for proton-pump inhibitor (PPI)-associated dysbiosis in metabolically unhealthy obesity
Burmeister, M. A., Smith, T. E., Fincher, T. K., & Weldon, A. J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1205490 · Cited by 16
“Compared to pretreatment values, human participants undergoing 8-week treatment with the PPIs esomeprazole, rabeprazole, or lansoprazole had increased fecal amounts of Firmicutes due to bacterial translocation from the oral, nasal, and throat cavities to the intestine (81).”
BackgroundSchumacher, J., Müller, P., Sulzer, J., Faber, F., Molitor, B., & Maier, L. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2519697 · Cited by 19
“18 The increase in Enterococcaceae and decrease in Ruminococcaceae are reproducible in our experiments when increasing the pH to 8 but not with omeprazole treatment.”
Hu, L., Lai, C., Li, Y. H., Sun, R., Yang, H., Liu, X., & Yu, P. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00848-x · Cited by 17
“↑ taxaincreaseinthegut, ↓ taxadepletioninthegut, H2S hydrogensul fi de, SCFAs short-chainfattyacids, SBA secondarybileacids, H2RAs histamine-2receptorantagonists, PPIs protonpumpinhibitor, P-CABs potassium-competitiveacidblockers, SNPs single nucleotidepolymorphism, NOD1 nucleotide-bindingoligomerization domain1”
InfluentialGan, L., Wang, Y., Huang, S., Zheng, L., Feng, Q., Liu, H., Liu, P., Zhang, K., Chen, T., & Fang, N. (2024) · Nutrients · doi:10.3390/nu16030342 · Cited by 11
“Although Streptococcus is one of the common genera of normal esophageal microorganisms [58], when gastric acid in the stomach is inhibited, and Streptococcus enters the lower digestive tract, it is often associated with some disease states [26,59,60].”
BackgroundResultKakiuchi, T., Tanaka, Y., Ohno, H., Matsuo, M., & Fujimoto, K. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-047941 · Cited by 12
López-Tenorio, I. I., Aguilar-Villegas, Ó. R., Espinoza-Palacios, Y., Segura-Real, L., Peña-Aparicio, B., Amedei, A., & Aguirre‐García, M. M. (2024) · Biomedicines · doi:10.3390/biomedicines12112529 · Cited by 13
Proton pump inhibitors: placing putative adverse effects in proper perspective
Schubert, M. L. (2019) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000580 · Cited by 9
The Human Gut Microbiota in all its States: From Disturbance to Resilience
Tap, J., Ruppé, É., & Derrien, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00039-5 · Cited by 9
Zhan, Z., Li, J., Zhang, W., Huang, S., & Fang, X. (2025) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.70436 · Cited by 7
“Long-term PPI use reduces stomach acid, prompting a gut environment shift that facilitates the translocation of proximal gut bacterial populations to the distal region and alters certain bacterial taxa abundances [39].”
Hypochlorhydria reduces mortality in heart failure caused by Kcne2 gene deletion
Lisewski, U., Köhncke, C., Schleußner, L., Purfürst, B., Lee, S. M., Silva, A. D., Manville, R. W., Abbott, G. W., & Roepke, T. K. (2020) · The FASEB Journal · doi:10.1096/fj.202000013rr · Cited by 7
Wu, Z., Wu, Y., Xiang, Z., Qiu, Y., Xuan, W., & Zhang, S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1713256 · Cited by 7
Kher, V., Wadhawan, M., Wadhwa, A., Shetty, S., Bhatnagar, S., Prabhoo, R. Y., Pai, U., Pillai, B. V., D'souza, C., Bhatnagar, M., et al. (2024) · Euroasian Journal of Hepato-Gastroenterology · doi:10.5005/jp-journals-10018-1430 · Cited by 8
“40,66 In cirrhotic patients, PPI therapy has been linked to disruptions in the gut microbiome, spontaneous bacterial peritonitis, and hepatic encephalopathy.”
BackgroundCui, X., Yin, L., Zhang, Y., Jiang, X., Li, L., & Bi, X. (2024) · BMC Oral Health · doi:10.1186/s12903-024-05000-3 · Cited by 8
“These adverse effects are believed to be linked to dysbiosis of the gastrointestinal tract induced by PPIs [6], characterized by an overgrowth of oral-associated bacteria known as oralization [7, 8].”
BackgroundSbeit, W., Khoury, T., Kadah, A., Asadi, W., Shahin, A., Lubany, A., Safadi, M., Haddad, H., Ahmad, R. A., Hija, S. A. E., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092966 · Cited by 6
“Accordingly, PPI-induced dysbiosis can increase the risk of bacterial enteric infections and translocation [9,15].”
BackgroundAthala, S. (2021) · JURNAL ILMIAH KESEHATAN SANDI HUSADA · doi:10.35816/jiskh.v10i2.616 · Cited by 5
“Penelitian terdahulu telah membuktikan kurkumin dapat mempengaruhi metabolisme asam arachidonat yaitu dengan menghambat aktivitas enzim siklooksigenase dan lipooksigenase (Hong et al., 2004).”
BackgroundHannan, N., Steel, A., Tiralongo, E., & McMillan, S. S. (2021) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2021.101448 · Cited by 5
Vandenplas, Y. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-67293-1.00021-9 · Cited by 5
Dumitru, C. N., Dumitru, A. O., Goroftei, L., Niculet, E., Ignat, M. D., Baroiu, L., Nechita, A., & Balan, G. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060651 · Cited by 4
The Relationship Between Functional Dyspepsia, PPI Therapy, and the Gastric Microbiome
Jagdish, B., & Kilgore, W. R. (2021) · Kansas Journal of Medicine · doi:10.17161/kjm.vol1414831 · Cited by 5
Costa, S. D. A. L., Marques, L. F., Aleixo, A. G., da Silva, L. F., Santos, N. V. P., de Caramalac, A. R., Neto, A. T., Castro, E. S., Fernandes, B. F., & Ayres, A. M. D. N. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n2-023 · Cited by 4
McMillan, A., Perez, C., & Brooks, A. E. (2023) · Medicine · doi:10.1097/md.0000000000035351 · Cited by 5
“[11] A recent study using quantitative RT-PCR, revealed PPI use was associated with gut dysbiosis.”
BackgroundMethodResultInfluentialSmall Intestinal Bacterial Overgrowth Syndrome
Dharmarajan, T. S., & Pitchumoni, C. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-30192-7_62 · Cited by 3
Sbeit, W., Abukaes, H., Ahmad, H. S., Sbeit, M., Kalisky, I., Katz, L. H., Mari, A., & Khoury, T. (2022) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2022.2106150 · Cited by 3
“ation of treatment has also increased [9].”
Passing the “Acid Test”: Do Proton Pump Inhibitors Affect the Composition of the Microbiome?
Dong, T. S., & Pisegna, J. R. (2018) · Digestive Diseases and Sciences · doi:10.1007/s10620-018-5273-3 · Cited by 5
Zhou, S., Yu, Y., Tian, J., Wang, X., Zeng, M., & Song, H. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1704508 · Cited by 2
“…reported that the gastrointestinal adverse events (such as diarrhea, abdominal bloating, and constipation) accompanying BQT treatment are partly caused by drug effects, such as antibiotic-associated diarrhea and PPI-induced intestinal microbiota disorders (Hojo et al., 2018; Motamedi et al., 2021).”
Lepczyńska, M., Dzika, E., Chen, W., & Lu, C. (2021) · Clinical and Translational Gastroenterology · doi:10.14309/ctg.0000000000000325 · Cited by 4
Long-term potassium-competitive acid blockers administration causes microbiota changes in rats
Najah, H., Edelmuth, R., Riascos, M. C., Grier, A., Asadi, H. A., Greenberg, J. A., Miranda, I. C., Crawford, C. V., Finnerty, B. M., Fahey, T. J., et al. (2023) · Surgical Endoscopy · doi:10.1007/s00464-023-10269-6 · Cited by 3
“This finding has previously been observed in PPI users [24, 25] and was associated with an increased risk of Clostridium difficile infection in several studies.”
Kim, J. H., Min, J., Jo, Y. W., Kwon, J., & Her, Y. (2023) · Journal of Korean Medical Science · doi:10.3346/jkms.2023.38.e402 · Cited by 2
Furune, S., Suzuki, T., Honda, T., Yamamoto, K., Furukawa, K., Nakamura, M., Ishigami, M., Kinoshita, F., Kadota, Y., Tochio, T., et al. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16445 · Cited by 3
“41 Although PPIs neither increase nor decrease SCFA levels in the gut, 42 no signi fi cant SCFA alterations were noted in the placebo group of this study.”
Lu, C., & Qiao, H. (2025) · Birth Defects Research · doi:10.1002/bdr2.2481 · Cited by 1
“(PPIs)—often require prolonged or lifelong administration, with therapeutic responses varying widely among patients (Badillo and Francis 2014; Hojo et al. 2018; Savarino et al. 2018).”
Lin, C., Ku, M.-K., Liu, H., Chou, H.-W., Chen, P., Wu, D., & Huang, Y. (2025) · Biological Trace Element Research · doi:10.1007/s12011-025-04857-x · Cited by 1
Hendem, E., KOÇAK, M. Z., Çetinkaya, A. M., Dinç, G., Çağlayan, M., Uğraklı, M., Çağlayan, D., Araz, M., Eryılmaz, M. K., Sakin, A., et al. (2026) · Medicina · doi:10.3390/medicina62010214 · Cited by 1
“PPIs are known to be associated with the gut microbiome, such as higher levels of Streptococcus , Bifidobacterium , and Lactobacillus [13].”
Naorem, R. S., Dutta, K., Bora, S. S., & Teli, A. B. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1781831 · Cited by 2
“…the abundance of Lactobacillus species is altered in individuals undergoing long-term PPI therapy, suggesting that these drugs may in fl uence bene fi cial gut microbial populations (Vesper et al., 2009; Freedberg et al., 2014; Jackson et al., 2016; Hojo et al., 2018; Kiecka and Szczepanik, 2023).”
Tanimaru, A. N., Mendes, A. B., de Mello, D. S. F., Mendes, F. G., & Carvalho, C. D. F. (2024) · Revista de Medicina · doi:10.11606/issn.1679-9836.v103i3e-210046 · Cited by 1
Kim, J. H., Min, J., Jo, Y. W., Kwon, J. W., & Her, Y. (2024) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.096 · Cited by 3
The role of in the development of small intestinal bacterial overgrowth syndrome
Kolmogorova, T. O., & Anchikova, T. A. (2019) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro2019803112 · Cited by 1
Acid suppression and effects on the gastrointestinal microbiome
Korus, H., & Vakil, N. B. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95070-1.00011-4 · Cited by 1
The impact of gastric acid suppression on the developing intestinal microbiome of a childPreprint
Spurr, A., Zhu, W., Wendy, S., Diez, M. B., Ian, L., Louis‐Jacques, O., Vilboux, T., Niederhuber, J. E., Shira, L. L., & Suchitra, K. H. (2021) · medRxiv · doi:10.1101/2021.12.21.21268064 · Cited by 1
“There have since been two smaller prospective studies comparing the gut microbiomes of adults before and after PPI use (23,24).”
BackgroundResultSmall Intestinal Bacterial Overgrowth Syndrome
Dharmarajan, T. S., & Pitchumoni, C. S. (2020) · Springer eBooks · doi:10.1007/978-3-319-90761-1_62-1 · Cited by 1
史新 (2007) · 广告导报
Publications from Juntendo University Graduate School of Medicine, 2018 [2/6]
(2020) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.2020.66.4-pl
Efeitos adversos do uso contínuo e irracional dos Inibidores de Bomba de Prótons em idosos
Calafiori, A. L. S., de Lima, A. A. B., Silva, J. I. M., Seraphim, J. C., da Silva, K. H., Silva, L. M. S., de Freitas, L. S., & Leite, N. A. A. (2022) · Brazilian Journal of Health Review · doi:10.34119/bjhrv5n5-012 · Cited by 3
de Souza, I. P., Rego, J. D. A., Machado, T. J. D. S., Fernandes, L. A., Silva, I. B., & Santos, A. A. Q. A. (2022) · Journal of Nutritional Health & Food Engineering · doi:10.15406/jnhfe.2022.12.00361
Hannan, N., Schloss, J. M., & Leach, M. (2023) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2023.09.002
Hayashi, S., Moriyama, T., Ito, Y., Harada, Y., Dodo, H., Kumahara, K., Yogi, T., Ohashi, N., Higashi, R., & Mori, A. (2024) · Japanese Journal of Infectious Diseases · doi:10.7883/yoken.jjid.2023.253
Pérez-Llano, B., Rodríguez, C. M., & Fraile, E. G. (2024) · Research Square · doi:10.21203/rs.3.rs-4026911/v1
Li, X., Chu, X., Cao, N., Wang, H., Fang, X.-Y., Fan, Y., Li, B., & Dong-qing, Y. (2022) · Figshare · doi:10.6084/m9.figshare.19669879
Llano, B. P., Rodríguez, C. M., & Fraile, E. G. (2026) · BMC Nutrition · doi:10.1186/s40795-026-01366-5
“Proton Pump Inhibitors (PPI) have been associated with a decrease in microbiota diversity and an increase of Lactobacilus , Steptococcus , Staphylococcus , and E.coli in two studies with 1815 and 20 subjects respectively [52, 55].”
Vandenplas, Y., Salvatore, S., Vercauteren, C., Huysentruyt, K., & Kindt, S. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11760-2.00021-5
Dietary Prebiotics Modulate Omeprazole‐Induced Alterations in the Gut Microbial Signature
Buccola, M. J., Babu, A. K. S., Paz, H. A., Porter, N. D., Srinivasan, H., Ricks, R. L., Rosquist, K., Torres, J. L., Zhong, Y., Jalili, T., et al. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70307
Metadata
- Authors
- Hojo, M., Asahara, T., Nagahara, A., Takeda, T., Matsumoto, K., Ueyama, H., Matsumoto, K., Asaoka, D., Takahashi, T., Nomoto, K., Yamashiro, Y., & Watanabe, S.
- Affiliations
- Juntendo University (JP)
- Juntendo Tokyo Koto Geriatric Medical Center (JP)
- Tokyo University of Agriculture (JP)
- Corresponding author
- Hojo, Mariko
- ORCID
- Venue
- Digestive Diseases and Sciences
- Published
- 2018-05-24
- Volume
- 63
- Issue
- 11
- Pages
- 2940-2949
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- PMC
- PMC6182435
- OpenAlex
- W2804467228
- Cited by
- 114
- References
- 62
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 12 · 2023: 15 · 2022: 11 · 2021: 28 · 2020: 15 · 2019: 8 · 2018: 1
- FWCI
- 4.62
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Yakult Honsha
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
- Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
- Keywords
- proton pump inhibitors, gut microbiota, reflux esophagitis, gut dysbiosis, Lactobacillus, Streptococcus, fecal pH, bacterial translocation, gastrointestinal infections, Lactobacillus gasseri, Lactobacillus fermentum, Lactobacillus reuteri, Lactobacillus ruminis
- MeSH terms
- Gastrointestinal Microbiome, Aged, Blood, Carboxylic Acids, Feces, Female, Humans, Male, Middle Aged, Proton Pump Inhibitors, Dysbiosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
